查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1968401

濾泡性甲狀腺癌治療市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、最終用戶、地區和競爭對手分類，2021-2031年

Follicular Thyroid Cancer Drug Sales Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球濾泡性甲狀腺癌治療市場預計將從 2025 年的 7.6 億美元成長到 2031 年的 10.7 億美元，複合年成長率為 5.81%。

這個市場領域主要包括針對轉移性或不可切除甲狀腺癌患者的標靶治療，例如蛋白酪氨酸激酶抑制劑和放射性碘療法。甲狀腺惡性腫瘤發生率的不斷上升以及識別需要特定藥物治療的基因突變的精準度不斷提高，是推動該行業成長的根本原因。根據美國癌症協會 (ACS) 的數據，預計到 2025 年，美國將新增 44,020 例甲狀腺癌病例，這一數字凸顯了對有效腫瘤治療方案的持續強勁的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 7.6億美元
市場規模：2031年 10.7億美元
複合年成長率：2026-2031年 5.81%
成長最快的細分市場 乳頭狀癌
最大的市場 北美洲

儘管成長要素強勁，但由於長期全身性治療帶來的嚴重毒性，市場仍面臨許多挑戰。這些不良反應常常迫使醫療專業人員減少劑量或完全停止治療，對患者的治療順從性和臨床療效產生負面影響。加上長期治療方法帶來的沉重經濟負擔，這些安全問題構成了重大障礙，可能阻礙全球濾泡性甲狀腺癌治療市場的發展和收入潛力。

市場促進因素

推動市場收入成長的關鍵因素是創新標靶治療（尤其是針對放射性碘抗藥性濾泡性甲狀腺癌的療法）的監管核准加速。臨床通訊協定正在迅速發展，從對晚期疾病療效有限的傳統特異性療法轉向針對特定路徑（例如VEGFR和RET）的蛋白酪氨酸激酶抑制劑（TKI）。領先的製藥研發公司強勁的財務業績表明，這種向高價值精準醫療的轉變顯而易見。例如，Exelixis公司在2024年11月公佈的第三季Cabozantinib系列藥物淨銷售額為4.781億美元，這充分體現了這些特異性治療方法的龐大市場價值。隨著監管機構不斷核准在無惡化生存期方面療效確切的藥物，市場單價和使用率持續上漲。

同時，全球甲狀腺惡性腫瘤發生率的上升擴大了目標患者群體，也使得診斷和治療資源的需求日益成長。這種疾病盛行率上升的趨勢在全球範圍內普遍存在，導致各個醫療保健系統對有效的管理策略的需求持續增加。加拿大癌症協會發布的《2024年加拿大癌症統計》報告估計，當年將有6,600名加拿大人被診斷出患有甲狀腺癌，凸顯了已開發國家日益沉重的負擔。患者數量的增加，加上基因組分析技術的進步，提高了標靶療法的商業性可行性。禮來公司宣布，其Letevmo產品2023年全年全球銷售額達到2.536億美元，證實了目標患者群體的擴大正在推動標靶治療領域的顯著銷售成長。

市場挑戰

長期全身性治療帶來的嚴重毒性持續限制著全球濾泡性甲狀腺癌治療市場的發展。強效藥物常引起不利事件，降低病人遵從性，迫使臨床醫師中斷或永久停止治療方案。治療中斷顯著縮短了平均治療持續時間，進而限制了每位患者的累積銷售額以及這些療法產生的總收入。

此外，不利事件的高發生率阻礙了相當一部分患者堅持用藥，使市場無法充分利用疾病的高發生率。鑑於需要長期治療的患者數量龐大，而他們正是該領域的核心基本客群，因此這個問題至關重要。根據美國癌症協會統計，到2025年，美國將有約859,890名女性甲狀腺癌倖存者，這意味著大量患者面臨因藥物毒性而中斷治療的風險。因此，由於安全問題導致長期藥物治療難以持續，直接阻礙了市場的整體成長。

市場趨勢

目前的治療格局正因聯合治療通訊協定研究的拓展而重塑。這源自於臨床醫師為克服進行性惡性腫瘤單藥治療的限制而做出的努力。研究人員正積極評估蛋白酪氨酸激酶抑制劑與其他藥物合併使用的方案，以期產生協同效應，延長對標準治療產生抗藥性的患者的無惡化生存期。LENVIMA等成熟藥物的商業性永續性體現了這種向多方面治療框架的策略轉變。Eisai在2025年5月發布的「2024會計年度合併會計業績」中報告稱，LENVIMA的全球銷售額達到3285億日元，這印證了該類治療層級在日益複雜且不斷擴展的治療格局中持續的高價值。

同時，免疫療法和免疫查核點抑制劑方案的出現，對於放射性碘抗藥性疾病患者而言是一項重大進展。這些生物製藥針對PD-1等通路，為腫瘤突變負荷高和微衛星不穩定性高的病例提供了新的作用機制，在激酶抑制劑無效或耐受性差時，提供了一種挽救性治療選擇。這一治療方法浪潮的大規模影響正在改變全球腫瘤領域的籌資策略，促使人們更加關注甲狀腺區域合格適應症中查核點抑制劑的可靠供應。根據默克公司2025年10月發布的第三季財報，Keytruda的全球銷售額達到81億美元，這反映了免疫腫瘤藥物在重新定義固體癌治療標準方面的主導作用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：濾泡性甲狀腺癌治療藥物的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（乳頭狀癌、濾泡狀癌、其他）
    • 依最終使用者（醫院/診所、門診中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美濾泡性甲狀腺癌治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲濾泡性甲狀腺癌治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區濾泡性甲狀腺癌治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲濾泡性甲狀腺癌治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲濾泡性甲狀腺癌治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球濾泡性甲狀腺癌治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • GlaxoSmithKline Plc
  • Novartis AG
  • Merck & Co
  • Pfizer Inc
  • Exelixis Inc
  • Celgene Corporation
  • Bayer AG
  • Eisai Co., Ltd
  • Teva Pharmaceuticals Industries Ltd.
  • AstraZeneca Pharmaceuticals LP

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23875

The Global Follicular Thyroid Cancer Drug Sales Market is projected to expand from USD 0.76 Billion in 2025 to USD 1.07 Billion by 2031, registering a CAGR of 5.81%. This market sector primarily consists of targeted therapies, such as tyrosine kinase inhibitors, alongside radioactive iodine treatments intended for patients with metastatic or unresectable conditions. The growth of this industry is fundamentally supported by the increasing prevalence of thyroid malignancies and the improved identification of genetic mutations that require specific pharmacological responses. Data from the American Cancer Society indicates that there were an estimated 44,020 new thyroid cancer diagnoses in the United States in 2025, a figure that highlights the substantial and steady demand for effective oncological solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 0.76 Billion
Market Size 2031USD 1.07 Billion
CAGR 2026-20315.81%
Fastest Growing SegmentPapillary Carcinoma
Largest MarketNorth America

Despite these robust growth drivers, the market encounters significant obstacles due to the severe toxicity profiles linked to long-term systemic therapies. These adverse effects frequently force medical practitioners to lower dosages or discontinue treatment altogether, which negatively affects patient adherence and clinical outcomes. When combined with the considerable economic strain of maintaining prolonged therapeutic regimens, these safety issues create a notable barrier that could hinder the broader development and revenue potential of the Global Follicular Thyroid Cancer Drug Sales Market.

Market Driver

A primary catalyst for revenue growth within the market is the accelerated regulatory approval of innovative targeted therapies, specifically for radioiodine-refractory follicular thyroid cancer. Clinical protocols are rapidly evolving to favor tyrosine kinase inhibitors (TKIs) that target distinct pathways like VEGFR and RET, replacing older, nonspecific treatments that provided limited efficacy in advanced disease stages. This transition toward high-value precision medicine is evidenced by the robust financial results of major pharmaceutical developers; for instance, Exelixis, Inc. reported in November 2024 that its cabozantinib franchise achieved net product revenues of $478.1 million during the third quarter, demonstrating the significant market value of these specialized interventions. As regulatory agencies continue to approve agents with proven benefits in progression-free survival, the market is experiencing a sustained rise in both unit price and utilization.

Simultaneously, the increasing global incidence of thyroid malignancies is enlarging the addressable patient population, necessitating a higher volume of diagnostic and therapeutic resources. This rising trend in disease prevalence is observed internationally, generating consistent demand for effective management strategies across various healthcare systems. The Canadian Cancer Society's 'Canadian Cancer Statistics 2024' report estimated that 6,600 Canadians would be diagnosed with thyroid cancer that year, underscoring the growing burden in developed nations. This expanding patient volume, coupled with advancements in genomic profiling, reinforces the commercial viability of niche drugs; Eli Lilly and Company noted that worldwide revenue for Retevmo grew to $253.6 million for the full year 2023, confirming how the growing pool of eligible patients drives substantial sales in the targeted therapy segment.

Market Challenge

The expansion of the Global Follicular Thyroid Cancer Drug Sales Market is continually impeded by the severe toxicity profiles associated with long-term systemic therapy. Potent pharmacological agents frequently trigger adverse events that undermine patient compliance, compelling clinicians to interrupt dosing schedules or permanently cease administration. This disruption in the treatment continuum significantly shortens the average duration of therapy, which in turn reduces the cumulative volume of drug units sold per patient and limits the total revenue generated from these therapeutics.

Furthermore, the market struggles to fully capitalize on disease prevalence because the high incidence of adverse events prevents a significant portion of the patient population from maintaining consistent adherence. This issue is critical given the large volume of patients requiring extended management who constitute the core customer base. According to the American Cancer Society, there were approximately 859,890 female thyroid cancer survivors in the United States in 2025, a statistic that illustrates the vast scale of the patient pool susceptible to toxicity-related discontinuation. Consequently, the difficulty in sustaining long-term pharmacologic regimens due to safety concerns directly hampers the market's overall growth trajectory.

Market Trends

The treatment landscape is currently being reshaped by the rising investigation of combination therapy protocols, as clinicians aim to surpass the limitations of monotherapy for aggressive malignancies. Researchers are actively evaluating regimens that pair tyrosine kinase inhibitors with other agents to produce synergistic effects and extend progression-free survival in patients who have developed resistance to standard care. This strategic pivot toward multi-modal frameworks is exemplified by the commercial resilience of established agents like Lenvima; Eisai Co., Ltd. reported in its 'Consolidated Financial Report for Fiscal 2024' in May 2025 that global revenue for Lenvima reached ¥328.5 billion, underscoring the sustained high value of this therapeutic class as it expands into complex treatment settings.

In parallel, the emergence of immunotherapy and immune checkpoint inhibitor regimens signifies a critical evolution for patients with radioiodine-refractory disease. By targeting pathways such as PD-1, these biologics offer a novel mechanism of action for cases exhibiting high tumor mutational burden or microsatellite instability, providing a salvage option when kinase inhibitors are ineffective or poorly tolerated. The massive scale of this therapeutic wave is influencing oncology procurement strategies globally, ensuring that checkpoint inhibitors are accessible for eligible niche indications within the thyroid segment. As reported by Merck & Co., Inc. in October 2025 regarding their third-quarter financial results, Keytruda generated worldwide sales of $8.1 billion, a figure that reflects the dominant role of immuno-oncology agents in redefining standards of care across solid tumors.

Key Market Players

  • GlaxoSmithKline Plc
  • Novartis AG
  • Merck & Co
  • Pfizer Inc
  • Exelixis Inc
  • Celgene Corporation
  • Bayer AG
  • Eisai Co., Ltd
  • Teva Pharmaceuticals Industries Ltd.
  • AstraZeneca Pharmaceuticals LP

Report Scope

In this report, the Global Follicular Thyroid Cancer Drug Sales Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Follicular Thyroid Cancer Drug Sales Market, By Type

  • Papillary Carcinoma
  • Follicular Carcinoma
  • Others

Follicular Thyroid Cancer Drug Sales Market, By End User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Follicular Thyroid Cancer Drug Sales Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Follicular Thyroid Cancer Drug Sales Market.

Available Customizations:

Global Follicular Thyroid Cancer Drug Sales Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Follicular Thyroid Cancer Drug Sales Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Papillary Carcinoma, Follicular Carcinoma, Others)
    • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Follicular Thyroid Cancer Drug Sales Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Follicular Thyroid Cancer Drug Sales Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Follicular Thyroid Cancer Drug Sales Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Follicular Thyroid Cancer Drug Sales Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End User

7. Europe Follicular Thyroid Cancer Drug Sales Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Follicular Thyroid Cancer Drug Sales Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Follicular Thyroid Cancer Drug Sales Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Follicular Thyroid Cancer Drug Sales Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Follicular Thyroid Cancer Drug Sales Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Follicular Thyroid Cancer Drug Sales Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Follicular Thyroid Cancer Drug Sales Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Follicular Thyroid Cancer Drug Sales Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Follicular Thyroid Cancer Drug Sales Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Follicular Thyroid Cancer Drug Sales Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Follicular Thyroid Cancer Drug Sales Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Follicular Thyroid Cancer Drug Sales Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Follicular Thyroid Cancer Drug Sales Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Follicular Thyroid Cancer Drug Sales Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Follicular Thyroid Cancer Drug Sales Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Follicular Thyroid Cancer Drug Sales Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End User

10. South America Follicular Thyroid Cancer Drug Sales Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Follicular Thyroid Cancer Drug Sales Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Follicular Thyroid Cancer Drug Sales Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Follicular Thyroid Cancer Drug Sales Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Follicular Thyroid Cancer Drug Sales Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GlaxoSmithKline Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Merck & Co
  • 15.4. Pfizer Inc
  • 15.5. Exelixis Inc
  • 15.6. Celgene Corporation
  • 15.7. Bayer AG
  • 15.8. Eisai Co., Ltd
  • 15.9. Teva Pharmaceuticals Industries Ltd.
  • 15.10. AstraZeneca Pharmaceuticals LP

16. Strategic Recommendations

17. About Us & Disclaimer